Published in Int J Obes (Lond) on April 25, 2006
PPAR delta as a therapeutic target in metabolic disease. FEBS Lett (2007) 1.38
Several genetic polymorphisms interact with overweight/obesity to influence serum lipid levels. Cardiovasc Diabetol (2012) 1.12
Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol (2010) 1.06
PPAR-delta in Vascular Pathophysiology. PPAR Res (2009) 0.87
Association of peroxisome proliferator-activated receptor α/δ/γ with obesity, and gene-gene interaction, in the Chinese Han population. J Epidemiol (2013) 0.85
Interaction between Calpain 5, Peroxisome proliferator-activated receptor-gamma and Peroxisome proliferator-activated receptor-delta genes: a polygenic approach to obesity. Cardiovasc Diabetol (2008) 0.81
Pathway Analysis of Metabolic Syndrome Using a Genome-Wide Association Study of Korea Associated Resource (KARE) Cohorts. Genomics Inform (2014) 0.80
Peroxisome proliferator-activated receptor delta (PPARD) genetic variation and type 2 diabetes in middle-aged Chinese women. Ann Hum Genet (2011) 0.79
Association of the variants in the PPARG gene and serum lipid levels: a meta-analysis of 74 studies. J Cell Mol Med (2014) 0.79
Role of peroxisome proliferator-activated receptors gene polymorphisms in type 2 diabetes and metabolic syndrome. World J Diabetes (2015) 0.77
Analysis on the association between PPARα/γ polymorphisms and lipoprotein(a) in a Chinese Han population. Mol Genet Genomics (2014) 0.76
Hematopoietic knockdown of PPARδ reduces atherosclerosis in LDLR-/- mice. Gene Ther (2015) 0.75
Screening of Peroxisome Proliferator-Activated Receptors (PPARs) α, γ and α Gene Polymorphisms for Obesity and Metabolic Syndrome Association in the Multi-Ethnic Malaysian Population. Ethn Dis (2015) 0.75
Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a) Circulation (1995) 2.01
Mutational spectrum in the Delta7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. Am J Hum Genet (2000) 1.61
Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med (2014) 1.48
Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem (2001) 1.43
Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation (1997) 1.43
Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia. Atherosclerosis (1991) 1.42
Different cis-acting DNA elements control expression of the human apolipoprotein AI gene in different cell types. Mol Cell Biol (1988) 1.35
Disruption of the sterol carrier protein 2 gene in mice impairs biliary lipid and hepatic cholesterol metabolism. J Biol Chem (2001) 1.24
Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPARalpha) in sterol carrier protein 2-/ sterol carrier protein x-deficient mice. J Biol Chem (1999) 1.21
Exercise-induced fibre type transitions with regard to myosin, parvalbumin, and sarcoplasmic reticulum in muscles of the rat. Pflugers Arch (1984) 1.17
Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest (2007) 1.15
Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. J Lipid Res (1999) 1.11
The high density lipoprotein- and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. Biochem Biophys Res Commun (1994) 1.10
A mutation in the enamelin gene in a mouse model. J Dent Res (2007) 1.10
Frequency gradients of DHCR7 mutations in patients with Smith-Lemli-Opitz syndrome in Europe: evidence for different origins of common mutations. Eur J Hum Genet (2001) 1.09
Porcine 80-kDa protein reveals intrinsic 17 beta-hydroxysteroid dehydrogenase, fatty acyl-CoA-hydratase/dehydrogenase, and sterol transfer activities. J Biol Chem (1996) 1.06
Aberrant oxidation of the cholesterol side chain in bile acid synthesis of sterol carrier protein-2/sterol carrier protein-x knockout mice. J Biol Chem (1999) 1.04
Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab (1999) 1.04
Increased efficiency of arbitrarily primed PCR by prolonged ramp times. Biotechniques (1999) 1.00
A polymorphism in the apolipoprotein A5 gene is associated with weight loss after short-term diet. Clin Genet (2005) 0.99
Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia. Clin Genet (2005) 0.99
Sterol carrier protein X (SCPx) is a peroxisomal branched-chain beta-ketothiolase specifically reacting with 3-oxo-pristanoyl-CoA: a new, unique role for SCPx in branched-chain fatty acid metabolism in peroxisomes. Biochem Biophys Res Commun (1997) 0.99
NMR structure of the sterol carrier protein-2: implications for the biological role. J Mol Biol (2000) 0.98
Studies on plasma lipoproteins during absorption of exogenous lecithin in man. J Lipid Res (1980) 0.97
Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor. Endocrinology (2001) 0.96
Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study. Int J Obes (Lond) (2008) 0.96
The single nucleotide polymorphism -1131T>C in the apolipoprotein A5 (APOA5) gene is associated with elevated triglycerides in patients with hyperlipidemia. J Mol Med (Berl) (2003) 0.95
High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway. Thromb Haemost (2001) 0.91
Heterozygosity for lysosomal acid lipase E8SJM mutation and serum lipid concentrations. Nutr Metab Cardiovasc Dis (2012) 0.90
Smith-Lemli-Opitz syndrome: treatment with cholesterol and bile acids. Neuropediatrics (1996) 0.89
Ipsi-and contralateral changes in rabbit soleus myosins by cross-reinnervation. Pflugers Arch (1981) 0.89
HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol (1998) 0.88
Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur J Endocrinol (1999) 0.88
Human lymphocytes produce urocortin, but not corticotropin-releasing hormone. J Clin Endocrinol Metab (1998) 0.86
Phosphorylation from inorganic phosphate and ATP synthesis of sarcoplasmic membranes. Eur J Biochem (1977) 0.86
Fatal genetic defect causing Wolman disease. J Inherit Metab Dis (1999) 0.86
Regulation of the human interleukin-2 gene by the alpha and beta isoforms of the glucocorticoid receptor. Mol Cell Endocrinol (1997) 0.86
Severe Tangier disease with a novel ABCA1 gene mutation. Neurology (2008) 0.86
Homozygosity for a splice junction mutation in exon 8 of the gene encoding lysosomal acid lipase in a Spanish kindred with cholesterol ester storage disease (CESD). Hum Genet (1995) 0.85
Identification of the newly discovered 58 kDa peroxisomal thiolase SCPx as the main thiolase involved in both pristanic acid and trihydroxycholestanoic acid oxidation: implications for peroxisomal beta-oxidation disorders. J Inherit Metab Dis (1998) 0.85
Steroids, fatty acyl-CoA, and sterols are substrates of 80-kDa multifunctional protein. Steroids (1997) 0.85
Cloning and sequencing of a novel murine liver carboxylesterase cDNA. Biochim Biophys Acta (1998) 0.85
Competition between oxalate and phosphate during active calcium accumulation by sarcoplasmic vesicles. Z Naturforsch C (1977) 0.85
Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry (2000) 0.85
Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet. Horm Metab Res (2007) 0.84
Neural control of gene expression in skeletal muscle. Calcium-sequestering proteins in developing and chronically stimulated rabbit skeletal muscles. Biochem J (1986) 0.84
NMR determination of the secondary structure and the three-dimensional polypeptide backbone fold of the human sterol carrier protein 2. FEBS Lett (1993) 0.84
Structure and chromosomal assignment of the murine sterol carrier protein 2 gene (Scp2) and two related pseudogenes by in situ hybridization. Cytogenet Cell Genet (1996) 0.82
Resequencing the apolipoprotein A5 (APOA5) gene in patients with various forms of hypertriglyceridemia. Atherosclerosis (2011) 0.82
Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease. Evidence for the involvement of phosphatidylcholine breakdown in HDL-mediated cholesterol efflux mechanisms. J Clin Invest (1996) 0.82
Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Mol Cell Endocrinol (1999) 0.82
Rare variants in the lipoprotein lipase (LPL) gene are common in hypertriglyceridemia but rare in Type III hyperlipidemia. Atherosclerosis (2010) 0.82
Phosphatidylcholine-specific phospholipase C regulates thapsigargin-induced calcium influx in human lymphocytes. J Biol Chem (1997) 0.81
Characterization of atherosclerosis in a patient with familial high-density lipoprotein deficiency. Atherosclerosis (1994) 0.80
Cerebrovascular atherosclerosis in type III hyperlipidemia is modulated by variation in the apolipoprotein A5 gene. Eur J Med Res (2011) 0.79
Coordinate expression of alkali and DTNB myosin light chains during transformation of rabbit fast muscle by chronic stimulation. FEBS Lett (1983) 0.79
Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas. Clin Endocrinol (Oxf) (2000) 0.79
HDL3 stimulates multiple signaling pathways in human skin fibroblasts. Arterioscler Thromb Vasc Biol (1995) 0.79
Effects of genotype and diet on cholesterol efflux into plasma and lipoproteins of normal, apolipoprotein A-I-, and apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (1997) 0.79
Neural control of gene expression in skeletal muscle. Effects of chronic stimulation on lactate dehydrogenase isoenzymes and citrate synthase. Biochem J (1986) 0.79
The non-specific lipid transfer protein (sterol carrier protein 2) acts as a peroxisomal fatty acyl-CoA binding protein. Biochem Soc Trans (1998) 0.78
Peroxisomes contain an enzyme with 17 beta-estradiol dehydrogenase, fatty acid hydratase/dehydrogenase, and sterol carrier activity. Ann N Y Acad Sci (1996) 0.78
Screening for atherosclerotic plaques in the abdominal aorta in high-risk patients with multicontrast-weighted MRI: a prospective study at 3.0 and 1.5 tesla. Br J Radiol (2010) 0.77
High density lipoproteins enhance the Na+/H+ antiport in human platelets. Thromb Haemost (1996) 0.77
Na(+)/Ca(2+) exchange inhibitors modulate thapsigargin-induced Ca(2+) and Na(+) influx in human lymphocytes. Int J Clin Lab Res (1999) 0.76
Stability and binding properties of wild-type and c17s mutated human sterol carrier protein 2. Biochim Biophys Acta (1999) 0.76
Expression of leukemia inhibitory factor (LIF) and LIF receptor (LIF-R) in the human adrenal cortex: implications for steroidogenesis. Mol Cell Endocrinol (2000) 0.76
Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate. Am J Med (1994) 0.76
HDL3 activates phospholipase D in normal but not in glycoprotein IIb/IIIa-deficient platelets. Biochem Biophys Res Commun (1995) 0.76
Diagnosis of Smith-Lemli-Opitz syndrome. N Engl J Med (1994) 0.75
[Primary prevention of cardiovascular diseases. Stepchild of internal medicine]. Internist (Berl) (2004) 0.75
Regulation of parvalbumin concentration in mammalian muscle. Methods Enzymol (1987) 0.75
Acrokeratoelastoidosis mimicking palmo-plantar xanthomata. Nutr Metab (1973) 0.75
A novel missense mutation (Gly2Arg) in the human lysosomal acid lipase gene is found in individuals with and without cholesterol ester storage disease (CESD). Clin Genet (1996) 0.75
Phospholipase A(2) is involved in thapsigargin-induced sodium influx in human lymphocytes. Arch Biochem Biophys (2000) 0.75
Vitamin B6 modulates glucocorticoid-dependent gene transcription in a promoter- and cell type-specific manner. Exp Clin Endocrinol Diabetes (2004) 0.75
Telomerase activity in benign and malignant adrenal tumors. Exp Clin Endocrinol Diabetes (1999) 0.75
Trials of the effects of drugs and hormones on lipids and lipoproteins. Curr Opin Lipidol (1995) 0.75
Lipase deficiencies. J Inherit Metab Dis (1988) 0.75
A missense mutation (Thr-6Pro) in the lysosomal acid lipase (LAL) gene is present with a high frequency in three different ethnic populations: impact on serum lipoprotein concentrations. Hum Genet (1996) 0.75
Alterations in phenotype expression of muscle by chronic nerve stimulation. Adv Exp Med Biol (1985) 0.75
[Molecular analysis of the human "growth hormone secretagogue"-receptor]. Med Klin (Munich) (1999) 0.75
Bimonthly update: lipidology. Genetics and molecular biology. Curr Opin Lipidol (1997) 0.75
D609-phosphatidylcholine-specific phospholipase C inhibitor attenuates thapsigargin-induced sodium influx in human lymphocytes. Cell Signal (2000) 0.75
[Acrokeratoelastoidosis]. Hautarzt (1974) 0.75
[Coronary angiography and intravascular ultrasound examination of a 60-year-old patient with familial HDL deficiency (Tangier disease)]. Z Kardiol (1994) 0.75
Genetics and molecular biology. Curr Opin Lipidol (1996) 0.75
[Postprandial lipemia and arteriosclerosis]. Dtsch Med Wochenschr (1992) 0.75
[Treatment of sudden hearing loss through Fibrinogen/LDL-apheresis. A prospective, randomized multicenter trial]. Z Kardiol (2003) 0.75
[Percutaneous transthyroidal instillation treatment of parathyroid adenoma with ethanol in primary hyperparathyroidism]. Dtsch Med Wochenschr (1987) 0.75
Carbon disulfide-induced modification and cytotoxicity of low-density lipoproteins. Toxicol In Vitro (1996) 0.75
[Hyperlipidemias]. Internist (Berl) (1991) 0.75
[Rationale for lipid therapy. Prevention or treatment of coronary heart disease?]. Herz (1997) 0.75